Clinical Trial Update: Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating evolocumab in ST-elevation myocardial infarction was withdrawn from the registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: ST-elevation Myocardial Infarction | Phase 2 | Status: WITHDRAWN